S
Shelly L. Carter
Researcher at Duke University
Publications - 73
Citations - 6686
Shelly L. Carter is an academic researcher from Duke University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 39, co-authored 73 publications receiving 6228 citations.
Papers
More filters
Journal ArticleDOI
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Claudio Anasetti,Brent R. Logan,Stephanie J. Lee,Edmund K. Waller,Daniel J. Weisdorf,John R. Wingard,Corey Cutler,Peter Westervelt,Ann E. Woolfrey,Stephen Couban,Gerhard Ehninger,Laura Johnston,Richard T. Maziarz,Michael A. Pulsipher,David L. Porter,Shin Mineishi,John M. McCarty,Shakila P. Khan,Paolo Anderlini,William I. Bensinger,Susan F. Leitman,Scott D. Rowley,Christopher Bredeson,Shelly L. Carter,Mary M. Horowitz,Dennis L. Confer +25 more
TL;DR: A phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors did not detect significant survival differences, and exploratory analyses of secondary end points indicated that peripheral- Blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduceThe risk of chronic GVHD.
Journal ArticleDOI
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
Claudio G. Brunstein,Ephraim J. Fuchs,Shelly L. Carter,Chatchada Karanes,Luciano J. Costa,Juan Wu,Steven M. Devine,John R. Wingard,Omar S. Aljitawi,Corey Cutler,Madan Jagasia,Karen K. Ballen,Mary Eapen,Paul O'Donnell +13 more
TL;DR: These multicenter studies confirm the utility of dUCB and Haplo-marrow as alternative donor sources and set the stage for a multicenter randomized clinical trial to assess the relative efficacy of these 2 strategies.
Journal ArticleDOI
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation
John R. Wingard,Shelly L. Carter,Thomas J. Walsh,Joanne Kurtzberg,Trudy N. Small,Lindsey R. Baden,Iris D. Gersten,Adam Mendizabal,Helen Leather,Dennis L. Confer,Richard T. Maziarz,Edward A. Stadtmauer,Javier Bolaños-Meade,Janice M. Brown,John F. DiPersio,Michael Boeckh,Kieren A. Marr,Kieren A. Marr +17 more
TL;DR: It is demonstrated that in the context of intensive monitoring and structured empiric antifungal therapy, 6-month FFS and overall survival did not differ in allogeneic HCT recipients given prophylactic fluconazole or voriconazole.
Journal ArticleDOI
Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation
Vincent T. Ho,Corey Cutler,Shelly L. Carter,Paul J. Martin,Roberta H. Adams,Mary M. Horowitz,James L.M. Ferrara,Robert J. Soiffer,Sergio Giralt +8 more
TL;DR: The toxicity committee of the Blood and Marrow Transplant Clinical Trials Network has reviewed the current literature on transplant-related HUS/TTP and recommends that it be henceforth renamed posttransplantation thrombotic microangiopathy (TMA), an operational definition for TMA based on the presence ofmicroangiopathic hemolysis and renal and/or neurologic dysfunction.
Journal ArticleDOI
Results of the Cord Blood Transplantation Study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies
Joanne Kurtzberg,Vinod K. Prasad,Shelly L. Carter,John E. Wagner,Lee Ann Baxter-Lowe,Donna A. Wall,Neena Kapoor,Eva C. Guinan,Stephen A. Feig,Elizabeth L. Wagner,Nancy A. Kernan +10 more
TL;DR: Unrelated donor cord blood transplantation from partially HLA-mismatched units can cure many children with leukemias.